Age of first pain crisis and associated complications in the CASiRe international sickle cell disease cohort.


Journal

Blood cells, molecules & diseases
ISSN: 1096-0961
Titre abrégé: Blood Cells Mol Dis
Pays: United States
ID NLM: 9509932

Informations de publication

Date de publication:
05 2021
Historique:
received: 30 08 2020
revised: 18 10 2020
accepted: 08 12 2020
pubmed: 6 1 2021
medline: 7 8 2021
entrez: 5 1 2021
Statut: ppublish

Résumé

Pain is a hallmark of Sickle Cell Disease (SCD) affecting patients throughout their life; the first pain crisis may occur at any age and is often the first presentation of the disease. Universal newborn screening identifies children with SCD at birth, significantly improving morbidity and mortality. Without early screening, diagnosis is generally made after disease manifestations appear. The Consortium for the Advancement of Sickle Cell Research (CASiRe) is an international collaborative group evaluating the clinical severity of subjects with SCD using a validated questionnaire and medical chart review, standardized across 4 countries (United States, United Kingdom, Italy and Ghana). We investigated the age of first pain crisis in 555 sickle cell subjects, 344 adults and 211 children. Median age of the first crisis in the whole group was 4 years old, 5 years old among adults and 2 years old among children. Patients from the United States generally reported the first crisis earlier than Ghanaians. Experiencing the first pain crisis early in life correlated with the genotype and disease severity. Early recognition of the first pain crisis could be useful to guide counseling and management of the disease.

Identifiants

pubmed: 33401140
pii: S1079-9796(20)30568-4
doi: 10.1016/j.bcmd.2020.102531
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

102531

Subventions

Organisme : NIMHD NIH HHS
ID : T37 MD001425
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Immacolata Tartaglione (I)

Department of Women, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy.

Crawford Strunk (C)

ProMedica Russell J. Ebeid Children's Hospital, Toledo, OH, USA.

Charles Antwi-Boasiako (C)

Department of Physiology, University of Ghana Medical School, University of Ghana, Accra, Ghana.

Biree Andemariam (B)

New England Sickle Cell Institute, Division of Hematology-Oncology, Neag Comprehensive Cancer Center, UCONN Health, University of Connecticut, Farmington, CT, USA.

Raffaella Colombatti (R)

Clinic of Pediatric Hematology Oncology, Department of Women's and Child Health, Azienda Ospedaliera-Università di Padova, Padova, Italy.

Eugenia Vicky Asare (EV)

Department of Hematology, Korle-Bu Teaching Hospital, Accra, Ghana.

Connie M Piccone (CM)

Pediatric Hematology/Oncology, Rainbow Babies and Children's Hospital, Cleveland, OH, USA.

Deepa Manwani (D)

Department of Pediatrics, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY, USA.

Donna Boruchov (D)

Department of Pediatrics, University of Connecticut School of Medicine, Connecticut Children's Medical Center, Hartford, CT, USA.

Fitz Tavernier (F)

Division of Pediatric Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.

Fatimah Farooq (F)

Division of Pediatric Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.

Sophia Akatue (S)

Division of Pediatric Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.

Bianca Oteng (B)

Division of Pediatric Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.

Rebekah Urbonya (R)

Division of Pediatric Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.

Samuel Wilson (S)

Division of Pediatric Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.

Ahmed Owda (A)

Division of Pediatric Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.

Rose Bamfo (R)

Division of Pediatric Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.

Gifty Dankwah Boatemaa (GD)

Department of Physiology, University of Ghana Medical School, University of Ghana, Accra, Ghana.

Sudha Rao (S)

Department of Child Health, University of Ghana Medical School Accra, Ghana.

William Zempsky (W)

Department of Pediatrics, University of Connecticut School of Medicine, Connecticut Children's Medical Center, Hartford, CT, USA.

Fredericka Sey (F)

Ghana Institute of Clinical Genetics, Korle Bu Teaching Hospital, Accra, Ghana.

Baba Pd Inusa (BP)

Department of Pediatric Haematology, Evelina Children's Hospital, Guy's and St. Thomas NHS Trust, London, UK.

Silverio Perrotta (S)

Department of Women, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy.

Catherine Segbefia (C)

Department of Child Health, University of Ghana Medical School Accra, Ghana.

Andrew D Campbell (AD)

Division of Pediatric Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA; Center for Cancer and Blood Disorders, Children's National Medical Center; George Washington University School of Medicine Health Sciences, Washington, DC, USA. Electronic address: acampbell@childrensnational.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH